Drug name - Pyrukynd

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785450 AGIOS PHARMS INC Therapeutic compounds and compositions
Feb, 2031

(8 years from now)

US11254652 AGIOS PHARMS INC Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Nov, 2038

(16 years from now)

CN104817498A AGIOS PHARMS INC Therapeutic Compound And Composition
Jun, 2030

(7 years from now)

CN102481300B AGIOS PHARMS INC Therapeutic Compound And Composition
Jun, 2030

(7 years from now)

CN104817498B AGIOS PHARMS INC Therapeutic Compounds And Compositions
Jun, 2030

(7 years from now)

CN102481300A AGIOS PHARMS INC Therapeutic Compounds And Compositions
Jun, 2030

(7 years from now)

IN381684B AGIOS PHARMS INC Therapeutic Compounds And Compositions
Jun, 2030

(7 years from now)

IN330578B AGIOS PHARMS INC Quinoline-8-Sulfonamide Compounds
Jun, 2030

(7 years from now)

IN201200471P1 AGIOS PHARMS INC Therapeutic Compounds And Compositions
Jun, 2030

(7 years from now)

IN201918008568A AGIOS PHARMS INC Therapeutic Compounds And Compositions
Jun, 2030

(7 years from now)

EP3241554B1 AGIOS PHARMS INC Quinoline-8-Sulfonamide Derivatives Having An Anticancer Activity
Jun, 2030

(7 years from now)

EP2448582A1 AGIOS PHARMS INC Quinoline-8-Sulfonamide Derivatives Having An Anticancer Activity
Jun, 2030

(7 years from now)

EP3241554A1 AGIOS PHARMS INC Quinoline-8-Sulfonamide Derivatives Having An Anticancer Activity
Jun, 2030

(7 years from now)

EP2448582A4 AGIOS PHARMS INC Therapeutic Compounds And Compositions
Jun, 2030

(7 years from now)

EP2448582B1 AGIOS PHARMS INC Quinoline-8-Sulfonamide Derivatives Having An Anticancer Activity
Jun, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682080 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy May, 2032

(9 years from now)

US9980961 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy May, 2032

(9 years from now)

US10632114 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy May, 2032

(9 years from now)

US9193701 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy Oct, 2032

(10 years from now)

US11234976 AGIOS PHARMS INC Methods of using pyruvate kinase activators Oct, 2038

(16 years from now)

Drugs and Companies using MITAPIVAT SULFATE ingredient

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription
EQ 50MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.